Royal Bank of Canada

RBC’s diversified retail, wealth‑management, and capital‑market model earns analyst upgrades & higher price targets—showing why investors view it as a resilient, growth‑oriented bank.

RBC’s early‑April 2026 research notes reveal cautious, conservative price upgrades across healthcare, energy, and tech, but leave key assumptions and social impacts largely unexplored.

RBC’s Q1 2026 earnings preview: capital‑market growth versus fee‑compression, regulatory costs, and a push toward green finance, fintech, and AI‑driven research.

RBC shares climb to new highs as analysts spotlight a strong Q1 earnings outlook, robust capital buffers, and a forward‑looking digital strategy that promises growth and income for investors.

RBC’s 2025 annual report shows a diversified, digitally‑enabled bank that grew 4.8% net income, boosted ESG‑aligned wealth and insurance sales, and leveraged tech to boost transaction‑processing margins, offering a clear, data‑driven view for invest…

RBC’s February research update gives institutional investors a clear look at semiconductor upside, commodity volatility, and ESG‑aligned credit and data‑analytics opportunities.

RBC’s upcoming Q1 earnings reveal hidden risks—declining margins, rising losses, and executive ties that may cloud performance and impact small‑business lending. Read our deep dive.

RBC earns a fresh buy rating as analysts praise its robust capital cushion, strong earnings, and AI‑driven growth strategy amid OSFI’s tougher liquidity rules.

RBC’s steady dividend policy, Canadian Tire partnership, and targeted energy research illustrate how the bank balances yield stability with growth in today’s volatile economy.

RBC’s latest U.S. equity research notes upgrade Medline Corp to “moderate buy” and give Phreesia Inc. an “outperform” rating, spotlighting growth in healthcare supply and digital health tech.